BSR Interviews
Whenever we are able, we like to sit down with industry executives and talk
with them about the business of biotechnology, their companies, and issues affecting the market as a whole. When things
work perfectly, we get to bring a tape recorder along so we can share the interview subject's own words with you. Most of these interviews were made available to our Subscribers one or two weeks before their posting to this free section of the site.
| Some of our interviews are available in the RealAudio format only. It is likely you have the ability to access RealAudio files already. If not, click on the logo at the right and you will be taken to the Real Networks site where you can get their RealPlayer for free. The other interviews are in the standard MP3 format. |
 |
CEO Tyrell and Pres. Canton, ViRexx
On January 17, 2007, BSR’s Alan Leong conducted a brief 18 minute interview of senior management from ViRexx Medical (REX), namely CEO Lorne Tyrell and President Marc Canton. The interview updates the status of the OvaRex cancer vaccine as well as the Chimigen and Occlusin platforms. |
Click here for details |
Dr. Jean-Jacques Bienaime, CEO, BioMarin
| This 19 minute interview gives a quick overview of BioMarin Pharmceuticals. It
has been 13 months since BSR’s original interview with Jean-Jacques
Bienaimé. The company has hit its milestones and is poised on the edge
of self-sustainability. CEO Bienaimé covers the current status of the
company product portfolio as well as upcoming milestones. BioMarin is a promising member of BSR's coverage universe. |
Click here for details |
Dr. Ira Lawrence, CEO, SciClone
| This 18 minute interview gives a quick overview of SciClone Pharmceuticals. It has been 12 months
since BSR did an audio interview with SciClone. We think you'll find it interesting, especially the company's
approach to China. SciClone is a promising member of BSR's coverage universe. |
Click here for details |
Dr. David L. Urdal, Pres. & CSO, Dendreon
| Dr. Urdal is perhaps one of the most knowledgeable individuals we have had the pleasure to interview. He is sharp as a tack and has an encyclopedic knowledge of the biotech industry and his company. As you listen to this nearly hour-long interview -- one of our most popular interviews to date, by the way -- you'll learn a great deal about Dendreon, more than a little about cancer vaccines, and how very good biotech executives think. | Click here for details |
Regulation Fair Disclosure Interview Series
| When the first of the three interviews in this series debuted in February of 2001, Reg. FD was only
four months old. One of the first comprehensive looks at Reg. FD post-implementation the articles and interviews in
this series accurately predicted the issues surrounding Reg. FD years after its debut. We interviewed an internal VP of Investor Relations, a 20-year veteran at an outside PR/IR firm, and a pair of securities lawyers. Accompanying each interview is an article that builds off of the interview, but is really its own stand-alone document. |
Click here for details |